Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib With Intravenous Bevacizumab With the Addition of Atezolizumab in Pediatric Solid Tumor Patients
This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamid…
Refractory Solid TumorHepatocellular CarcinomaMalignant Solid Tumor+3 more
St. Jude Children's Research HospitalNCT05468359
Phase 2
The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellu…
Hepatocellular Carcinoma, ChildhoodFibrolamellar CarcinomaLiver Cancer+1 more
Allison O'Neill, MDNCT04134559
Phase 1
A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma
This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and interferon alpha 2b work for the treatment of fibrolamellar cancer (li…
Stage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8+4 more
M.D. Anderson Cancer CenterNCT04380545
Phase 1
DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolesc…
Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar CarcinomaRecurrent Childhood Malignant Solid Neoplasm+6 more
Children's Oncology GroupNCT06620302